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Strengths and limitations of this study 
Strengths 
• Broad search strategy planned in order to identify a range of individual prognostic variables 
and multidimensional scores 
• A focus on prognostic variables available in clinical practice (rather than eg genomics), such 
that the results will be meaningful to current practice  
• Use of validated protocols and tools for data extraction, risk of bias assessment and 
reporting 
Limitations 
• Search restricted to patients with relatively stable disease, so we are unable to comment on 
prognostic variables of most use during or immediately after an exacerbation 
• Despite rigorous use of protocols there is a subjective element to any quality or risk of bias 
assessment 
Abstract 
Introduction: People living with advanced Chronic Obstructive Pulmonary Disease (COPD) suffer 
from significant morbidity, reduced quality of life and high mortality, and are likely to benefit from 
many aspects of a palliative care approach. Prognostic estimates are a meaningful part of decision-
making and better evidence for such estimates would facilitate advance care planning. We aim to 
provide quality evidence on known prognostic variables and scores which predict a prognosis in 
COPD of less than 12 months for use in the community. 
Methods and analysis: We will conduct a systematic review of randomised or quasi-randomised 
controlled trials, prospective and retrospective longitudinal cohort and case-control studies on 
prognostic variables, multivariate scores or models for COPD. The search will cover the period up to 
April 2016. Study selection will follow the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines, with data extraction using fields from the Critical Appraisal and 
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Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS) Checklist for 
multivariate models, and study quality will be assessed using a modified version of the Quality In 
Prognosis Studies (QUIPS) tool.  
Ethics and dissemination: The results will be disseminated through peer-reviewed publications and 
national and international conference presentations. 
Trial registration number: International Prospective Register for Systematic Reviews (PROSPERO) 
number CRD42016033866 
Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous collection of conditions 
characterized by progressive irreversible expiratory airflow limitation. The prevalence of COPD is 
increasing globally and it is projected to be not only the third leading cause of death, but also the 
seventh leading cause of disability adjusted life years (DALYs) lost worldwide by 2030, representing 
an important public health challenge(1). Patients with advanced COPD have significant morbidity, 
reduced quality of life and high mortality (2–6).  
Despite national(7)
 
and international(8) guidelines recommending a palliative care approach in 
severe COPD, patients are unlikely to access specialist services or elements of ‘general’ palliative 
care such as advance care planning, promotion of physical and psychosocial health and family or 
carer support (6,9–12). Systematic identification of patients approaching the “end-of-life” is a key 
recommendation of the end-of-life care strategy (13). The unpredictable disease trajectory of 
COPD(14) makes this difficult. Policy literature uses the last year of life as the measure of those who 
are approaching death, and states that identification of this group is the first step in any palliative 
care process. However, there is no ‘gold standard’ method for predicting prognosis in COPD, and no 
clear guidance on how to identify those in the last year of life. Easily measurable physiological 
parameters do not correlate well with mortality for individuals(15). There are alternative methods 
for identifying patients who may benefit from specific services, such as needs-based assessment 
(16).However, there are growing calls from patients, healthcare professionals and policy makers for 
better tools to aid prognostication which they see as a meaningful part of decision-making(17,18)
. 
Clinician predictions of survival are often inaccurate, and improvement in accuracy of prognostic 
tools has been identified as a research priority(19). 
A number of variables have been identified which are useful in making predictions about prognosis 
in COPD, in addition to the degree of airflow obstruction which was the historical way of staging the 
disease(20). Scores which combine a number of variables have also been developed, in recognition 
of the fact that COPD is a multisystem disease. None of these scores are in widespread routine 
clinical use. This is partly because some variables used in these scores are not captured during 
routine care. The most well validated prognostic score in COPD is the BODE (Body Mass Index (BMI), 
FEV1% (forced expiratory volume in 1 second, % predicted for age and sex), MRC dyspnoea (Medical 
Research Council dyspnoea score), 6MWT (6 minute walk test)) index(21). However, this has 
significant limitations as it requires a 6MWT, not routinely performed or recorded in primary care. A 
modification of the BODE score, the ADO(22) (age, MRC dyspnoea, FEV1%)
 
has been developed to 
address this problem. These scores were developed in small cohorts, although efforts to modify and 
validate them in larger cohorts and different settings have demonstrated some external validity(23–
25).  
A systematic review of multidimensional prognostic indices in COPD searched the literature up to 
September 2010(26). This study will have some important differences: we will consider the strength 
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and utility not only of composite scores but also individual prognostic variables. The only outcome of 
interest will be mortality, and not exacerbation or hospitalisation; and our focus will specifically be 
on prediction of prognosis towards the end of life (<12 months). 
Methods and analysis 
Aim: We aim to investigate known prognostic variables and scores which predict prognosis in COPD. 
We are specifically interested in those variables that contribute to risk assessment of patients in the 
community (ie not hospitalised) for death within less than 12 months. In developing this protocol we 
referred to the PRISMA-P 2015 statement(27), a guide for the standard reporting of systematic 
review protocols.  
Inclusion criteria (participants, interventions, comparisons and outcomes):  
Participants: Adults ≥ 35 years old with COPD as defined by GOLD(1).  
Interventions: We will include all randomised or quasi-randomised controlled trials, and prospective 
and retrospective longitudinal cohort and case-control studies which investigate prognostic 
variables, multivariate scores or models for COPD. We will include studies which describe the 
development, validation or impact assessment of prediction models.  
Comparisons: Comparators and controls are less relevant in prognostic than intervention studies and 
may be absent in cohort studies.  
Outcomes: The primary outcome of interest will be all cause mortality ≤12months following 
recording of prognostic variable or score  
Exclusion criteria:  
We will exclude the following literature: abstracts only (eg conference paper), case studies and 
reviews; studies that are on patients with alpha-1-antitrypsin deficiency, or those who have 
undergone lung transplantation, lung volume reduction surgery or comparative interventional 
bronchoscopic procedures; studies in which the diagnostic criteria for COPD is unclear or does not 
meet GOLD criteria; studies in which people with COPD form a subgroup and no separate reporting 
is available; studies requiring hospitalisation to acquire or measure the prognostic variable or score ; 
studies examining short-term prognosis following an exacerbation or hospitalisation; studies that 
investigate prognostic markers not easily available in clinical practice (eg biomarkers in 
development, invasive investigations); and studies in which the only exposure is occupational or 
environmental (eg air pollution).  
Literature search:  
We will search Ovid MEDLINE, EMBASE, the Cochrane database, Cochrane CENTRAL, DARE and 
CINAHL up to 30
th
 April 2016. We will use medical subject heading and text words related to COPD, 
and broad strategies to identify prognostic studies and prognostic markers, focused on advanced 
disease and the end of life (see Figure 1). Recognizing potential limitations of electronic search 
strategies, we will supplement our search to identify potentially relevant studies from other sources 
including reference lists of included studies, index-related articles on Pubmed, and existing relevant 
reviews as well as Google Scholar search and ProQuest. Where necessary authors will be contacted 
directly.  
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Selection of studies and extraction of data:  
Two authors  will scan the titles and abstracts of all literature retrieved by the initial search against 
inclusion and exclusion criteria and select articles for full-text review. All data will be downloaded to 
Zotero (28) for data management. Two authors will review the full text articles to assess eligibility 
for inclusion in the report. Differences of opinion will be resolved by consensus, or by arbitration by 
a third reviewer. The authors will extract data independently using a pre-specified data extraction 
tool. This will include details of the study setting, study design, population, diagnostic criteria for 
COPD (including cut-points for FEV1% predicted), method of measurement of each prognostic 
variable, and outcome definition. In addition it will include fields relevant to multivariate models 
based on the CHARMS checklist (29) such as modelling method, handling of predictors, method for 
selection of predictors, shrinkage of predictor weights, univariate and multivariate associations, 
model performance and evaluation. This will be piloted on the first 5 full text reviews to ensure 
standardised use of the tool. The process of literature selection and reasons for exclusion will be 
fully documented and a PRISMA(27) flow-diagram will be constructed.  
Quality assessment: 
Two reviewers will assess quality and risk of bias of eligible studies based on pre-specified domains. 
We will use an approach based on the QUIPS tool(30), specifically designed for prognostic reviews. 
We will consider questions under six domains: study participation and attrition, prognostic factor 
measurement, outcome measurement, confounding measurement and account, analysis, and other. 
Consensus will be reached by discussion, or by arbitration by a third reviewer.  
Data synthesis  
Due to clinical and methodological heterogeneity in potentially included studies identified in the 
scoping review, it is not expected that formal meta-analysis will be possible. The planned method for 
evidence synthesis is therefore a narrative synthesis of all identified evidence. We will summarise 
the range of outcome predictors that have been studied to date. With regard to composite scores 
we will assess not only the quality of model building, but also the degree to which the scores have 
been externally validated and to what degree clinical utility and impact has been assessed.  
 
We anticipate that many of the studies will be in restricted populations, such as trial populations, 
that may not represent the population of COPD patients in the community. We will thus be 
cognisant of and comment on possible spectrum bias(31) and the implications for generalisability of 
findings. An assessment of the strength of evidence for each prognostic variable or score included 
will be formulated based on GRADE evidence profiles(32).  
Ethics and dissemination 
No ethical approval is required, since this study is a synthesis of published studies. The results will be 
submitted for peer-reviewed publication and will be presented at national and international 
conferences.  
The protocol has been registered in the PROSPERO database: CRD42016033866. Any amendments 
to the study protocol will be documented contemporaneously on the PROSPERO database site.  
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Figure 1: example Ovid search strategy, developed with the help of a medical librarian  
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PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to 
address in a systematic review protocol*  
Section and topic Item 
No 
Checklist item Page 
ADMINISTRATIVE INFORMATION  
Title:    
 Identification 1a Identify the report as a protocol of a systematic review 1 
 Update 1b If the protocol is for an update of a previous systematic review, identify as such NA 
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number 1 
Authors:    
 Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding 
author 
1 
 Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review 6 
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; 
otherwise, state plan for documenting important protocol amendments 
4 
Support:    
 Sources 5a Indicate sources of financial or other support for the review 6 
 Sponsor 5b Provide name for the review funder and/or sponsor 6 
 Role of sponsor 
or funder 
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol 7 
INTRODUCTION  
Rationale 6 Describe the rationale for the review in the context of what is already known 1-2 
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, 
and outcomes (PICO) 
2-3 
METHODS  
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years 
considered, language, publication status) to be used as criteria for eligibility for the review 
2-3 
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey 
literature sources) with planned dates of coverage 
3 
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 3 
Study records:    
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 Data 
management 
11a Describe the mechanism(s) that will be used to manage records and data throughout the review 4 
 Selection 
process 
11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that 
is, screening, eligibility and inclusion in meta-analysis) 
4 
 Data collection 
process 
11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes 
for obtaining and confirming data from investigators 
4 
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions 
and simplifications 
4 
Outcomes and 
prioritization 
13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 3 
Risk of bias in 
individual studies 
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or 
study level, or both; state how this information will be used in data synthesis 
4 
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised NA 
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of 
combining data from studies, including any planned exploration of consistency (such as I
2
, Kendall’s τ) 
NA 
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) NA 
15d If quantitative synthesis is not appropriate, describe the type of summary planned 4 
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) 4 
Confidence in 
cumulative evidence 
17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 4 
*
 
It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important 
clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the 
PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. 
 
 
From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and 
meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647. 
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